EMERGENT BIOSOLUTIONS

Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023

06 2 2023 15:05:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus

09 1 2023 05:59:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

05 1 2023 16:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for Over-the-Counter NARCAN® (naloxone HCl) Nasal Spray

06 12 2022 05:00:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Receives Department of Defense Award to Evaluate Chikungunya Vaccine Candidate in Post-Approval Field Efficacy Study Using Model-Guided Approach

14 11 2022 05:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results For Third Quarter 2022

08 11 2022 15:16:51 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Presents Data from Phase 2 Study Evaluating Safety and Immunogenicity of Chikungunya Vaccine Candidate in Prior Recipients of Other Alphavirus Vaccines

01 11 2022 15:05:14 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Release Third Quarter 2022 Financial Results and Conduct Conference Call on November 8, 2022

18 10 2022 05:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

26 9 2022 15:12:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Initiates Phase 1 Study Evaluating Lassa Virus Vaccine Candidate

06 9 2022 05:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

10 8 2022 05:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Reports Financial Results for Second Quarter 2022

01 8 2022 15:05:47 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Release Second Quarter 2022 Financial Results and Conduct Conference Call on August 1, 2022

18 7 2022 15:05:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions and Ridgeback Biotherapeutics Enter Into Agreement for Ebanga™ Treatment for Ebola

07 7 2022 15:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Appointment of Sujata Dayal to Board of Directors

06 7 2022 15:05:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces FDA Acceptance of Biologics License Application for AV7909 Anthrax Vaccine Candidate

24 6 2022 05:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases

21 6 2022 05:30:00 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Participate in Investor Conferences

02 6 2022 07:20:49 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Acquire from Chimerix its Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages

16 5 2022 05:32:17 提供 Nasdaq GlobeNewswire

Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT

12 5 2022 05:30:00 提供 Nasdaq GlobeNewswire